Alkermes

Alkermes published Phase‑2 data from the Vibrance‑1 study in 92 adults with narcolepsy type 1. Once‑daily doses of 4, 6 or 8 mg Alixorexton produced statistically significant improvements in excessive daytime sleepiness; all dose groups achieved mean Maintenance of Wakefulness Test values of at least 20 minutes and Epworth scores of ≤10 at week 6. In the 6‑mg group the weekly cataplexy rate fell versus placebo; the drug was generally well tolerated and no serious adverse events occurred. Based on these results, a global Phase‑3 program (Brilliance Studies) is now under way; Alixorexton has received Breakthrough Therapy and Orphan Drug status in the US for certain indications. » Plus sur de.investing.com

Alkermes has agreed an amendment to its loan agreement that reduces the interest margins on its secured senior term loans. The adjustment lowers the margin on the TLA facility by 0.75 percentage points and on the TLB facility by 0.50 percentage points; TLA has an outstanding amount of USD 745.3m (maturity Feb. 12, 2031), TLB USD 773.1m (maturity Aug. 12, 2031). After the amendment, TLA will bear interest at Term SOFR plus 1.75–2.25% or Alternate Base Rate plus 0.75–1.25% depending on net leverage, and TLB at Term SOFR plus 2.25% or Alternate Base Rate plus 1.25%. The agreement was made with several lenders, including JPMorgan Chase and BofA Securities as arrangers. » Plus sur de.investing.com

Alkermes beat expectations in Q2 2026 with adjusted EPS of $0.00 and revenue of $496 million (+27% y/y), but was weighed down by a 2026 revenue forecast of $1.785 billion that missed the analyst consensus. The stock fell about 5.2% premarket to $50.00 as investors took profits after a strong rally year-to-date. Narcolepsy drug LUMRYZ contributed significantly to revenue, but integration costs and the muted outlook clouded sentiment. Piper Sandler raised its price target to $65 and reiterated “Overweight,” but that did not halt the short-term decline. » Plus sur de.investing.com